TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF) My Fellow Shareholders, Further to my previous letter of August 15, 2024, we wish to remind you of the reasoning behind the strategic decision to divest Lifeist of CannMart Inc. ("CannMart") via a sale to Simply Solventless Concentrates Ltd. ("SSC") per our press release of June 25, 2024, and why shareholders should vote in favor of the transaction at the Annual and Special Meeting on September 5 ...

Core Insights - Lifeist Wellness Inc. is expanding its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. by partnering with impact.com to enhance its affiliate marketing strategy, which is crucial for growth in the nutraceutical industry [1][3][4] - The global partnership and affiliate marketing market was valued at $20.4 billion in 2022 and is projected to grow to $39.8 billion by 2031, indicating significant potential for revenue generation in this sector [3] Company Overview - Lifeist Wellness Inc. focuses on leveraging advancements in science and technology to create innovative ventures aimed at transforming human wellness, with Mikra specializing in cellular health products [5][7] - Mikra aims to utilize impact.com's tools to effectively manage and optimize partnerships, thereby driving sales growth and customer acquisition [3][4] Industry Context - The partnership and affiliate marketing sector is experiencing rapid growth, driven by the rise of social media and decentralized media platforms, which allow diverse voices to reach broader audiences [3] - impact.com is recognized as a leading partnership management platform, supporting over 225,000 active partnerships for major brands, which highlights the importance of strategic partnerships in customer acquisition [6]

Core Viewpoint - LifeStance Health Group (NASDAQ:LFST) is positioned for continued growth due to its strong value proposition in mental health care and the increasing prevalence of mental illness in the US [2][16]. Company Overview - LFST operates a health provider platform offering mental health care through a hybrid model of in-person and telehealth services, primarily in the United States [3]. - In Q2 2024, LFST reported total revenue of $312 million, exceeding consensus expectations and reflecting a 20.3% year-over-year growth, driven by a 5% increase in revenue per clinician [3]. - The company expanded its clinician base by 14% in the quarter, totaling 6,984 clinicians [3]. - Adjusted EBITDA for Q2 2024 was $28.6 million, significantly above consensus estimates and management guidance, with an adjusted EBITDA margin of 9.2%, up 370 basis points year-over-year [3][10]. - Management raised FY24 revenue guidance to $1.20–$1.242 billion and adjusted EBITDA guidance to $90–$100 million, with positive free cash flow expected for the full year [3]. Growth Potential - LFST's hybrid model enhances accessibility for patients, reducing time and psychological barriers associated with seeking mental health care [4][5]. - The model allows LFST to reach a wider geographical area and capture untapped patient demand, leading to increased utilization of clinician services [6]. - The prevalence of mental illness in the US is significant, with over 1 in 5 adults affected, indicating a growing market for LFST's services [7]. Profit Margin Trends - LFST has shown improvement in its adjusted EBITDA margin, which is expected to reach double digits by FY25, supported by operational efficiencies and increased revenue [9][10]. - Despite a projected decrease in margin for Q3 2024, this is attributed to seasonal trends and proactive investments by management to enhance future performance [10]. Valuation Insights - LFST is projected to achieve approximately $1.4 billion in revenue by FY25, with an adjusted EBITDA margin of around 10% [13]. - The company is valued at a forward EBITDA multiple of 21x, which is considered attractive compared to peers, particularly given its higher profitability [12][14].

TORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, is pleased to announce that its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. ("Mikra") invites customers to sign up for VIP Early Access to the FOCUS Pre-Sale at https://wearemikra.com/pages/focus-signup-page. Mikra's n ...

TORONTO, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, is pleased to report that it has completed, pursuant to a share purchase agreement entered into on August 16, 2024 with an arm's length party, the acquisition of the shares of 1000594871 Ontario Corp. ("4871") which holds key intell ...

TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF) My Fellow Shareholders, In response to inquiries from many of you, we wish to set forth the reasoning behind the strategic decision to divest Lifeist of CannMart Inc. ("CannMart") via a sale to Simply Solventless Concentrates Ltd. ("SSC") under the terms of the agreement set forth in our press release of June 25, 2024. The decision to sell CannMart is the result of careful consideration by the Li ...

LifeStance Health Group (LFST) closed the last trading session at $5.84, gaining 3.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.14 indicates a 39.4% upside potential. The average comprises seven short-term price targets ranging from a low of $6 to a high of $10, with a standard deviation of $1.46. While the lowest estimate indicates an increase of 2.7% from the current pri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Common Stock, par value $0.01 per share LFST The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40478 | --- | --- | |------------------------------------ ...

LifeStance Health Group, Inc. (NASDAQ:LFST) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Monica Prokocki - Vice President of Investor Relations Ken Burdick - Chief Executive Officer Dave Bourdon - Chief Financial Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Lisa Gill - JPMorgan Jack Senft - William Blair Dylan Finley - UBS Jack Slevin - Jefferies Stephanie Davis - Barclays Operator Thank you for standing by. My name is Jermanie, and I will be your ...

| --- | --- | |-------------|-------| | | | | | | | | | | | | | Reimagining | | Forward-Looking Statements DISCLAIMERS Cautionary Note Regarding Forward-Looking Statements This presentation and related oral statements, including during any question and answer portion of the presentation, contain forward-looking statements about LifeStance Health Group, Inc. and its subsidiaries ("LifeStance") and the industry in which LifeStance operates, including statements regarding: full-year and third quarter guidance ...